A delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated new drug application) received final approval in the December 2024 quarter while 56 were still pending. According to YES Securities, the revenue contribution of the new approvals will likely be weak in the March quarter. A delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated new drug application) received final approval in the December 2024 quarter while 56 were still pending. According to YES Securities, the revenue contribution of the new approvals will likely be weak in the March quarter. Economic Times
Headlines
